In the world of life sciences, the pursuit of speed and responsibility in the development and commercialization of assets has been an ongoing challenge. The mantra "faster, better, cheaper" has echoed through the industry since the 1990s and Clinical Research Organizations (CROs) have stepped up to the plate to answer this call. While they have been successful in fitting themselves operationally to support the industry's ambitions, they have also created rigidity in delivery models.
The CRO industry offers both full-service and Functional Service Provider (FSP) solutions, with FSPs providing specific services and being in high demand by more significant sponsors. The FSP market is expected to reach $21 billion by 2027. However, traditional CROs rely on scale-based economic models that favor bigger companies. While some have created biotech arms to focus on smaller programs, this solution still follows the same financial framework as their larger counterparts.
A customized solution that combines traditional services with functional expertise and peer-to-peer collaboration, could benefit the industry and lead to better patient outcomes by increasing diversity and the number of products reaching the market.
For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies.
As the world's largest Research Consulting Organization (RCO), ProPharma partners with its clients through an advise-build-operate model to offer unparalleled drug development and medical device consulting expertise across the complete product lifecycle. Unlike traditional CROs, ProPharma's RCO model leads with strategy to enable the co-creation of optimal solutions to maximize the probability of success and reduce risk for clients.
With deep domain expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs.
ProPharma's global team of over 2,500 professionals spans six continents and is uniquely positioned to provide critical support services to pharmaceutical, biotechnology, and medical device clients worldwide. The company focuses on bringing novel therapies to market quickly and safely, underscoring its commitment to advancing the future health of the global population and improving patient outcomes.
The company has built a bespoke, fit-for-purpose, and flexible solution with the resources each sponsor needs at any point in their development continuum. The innovative RCO model provides deep scientific and technical expertise, ensuring sponsors are supported and expertly advised by industry leading Subject Matter Experts (SMEs) to meet all the nuances of the process and maximize successful outcomes. Matthew Weinberg, President, Regulatory Sciences at ProPharma, explains that the model has provided for more creative problem-solving and strategic collaboration without limitation.
Furthermore, the company's regulatory sciences service line encompasses deep regional expertise, superior knowledge, and executive leadership backed by the tactical know-how to structure complicated trials and deliver results.
This enables the customized design and delivery of consulting solutions equipped to navigate the increasingly complex global regulatory environment successfully. The RCO model is a game-changer for the world of life sciences, and ProPharma is at the forefront of this revolution.
